factual

Accelerated approvals are rarely revoked or confirmed

It would be acceptable to allow uncertainty at market entry in exchange for speed if that uncertainty were later resolved and ineffective drugs were withdrawn, but the FDA almost never removes drugs from the market and has a poor track record of ensuring post-market confirmatory studies get done; when they are done, 20% of the time the drug is converted to full approval on the same surrogate endpoint, which doubles down on the uncertainty rather than eliminating it.

factualpending

Speaker

Vinay Prasad

Evidence Quote

“Not only do they never, almost never take it off the market, they have a poor track record of making sure those studies get done--the post-market, confirmatory studies.”

Source

Vinay Prasad on Cancer Drugs, Medical Ethics, and Malignant— EconTalk
Created: 6/13/2026, 12:28:36 AM

Your notes

Loading notes...